Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith, Arnold B. Gelb, Huiling Xiong, Janet Hong, Vikram Chand, Howard Safran

ABSTRACT

BACKGROUND: We evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy. METHODS: In a phase 1b expansion cohort, patients without (1 L-mn) or with (2 L) disease progression following first-line chemotherapy for advanced GC/GEJC received avelumab 10 mg/kg intravenously every 2 weeks. Endpoints included best overall response, progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Overall, 150 patients were enrolled (1 L-mn, n = 90; 2 L, n = 60) and median follow-up in the 1 L-mn and 2 L subgroups was 36.0 and 33.7 months, respectively. The confirmed objective response rate was 6.7% in both subgroups (95% CI, 2.5-13.9% and 1.8-16.2%, respectively), including complete responses in 2.2% of the 1 L-mn subgroup (n = 2). In the 1 L-mn and 2 L subgroups, median duration of response was 21.4 months (95% CI, 4.0-not estimable) and 3.5 months (95% CI, 2.8-8.3) and disease control rates were 56.7 and 28.3%, respectively. Median PFS in the 1 L-mn and 2 L subgroups was 2.8 months (95% CI, 2.3-4.1) and 1.4 months (95% CI, 1.3-1.5), with 6-month PFS rates of 23.0% (95% CI, 14.7-32.4%) and 7.9% (95% CI, 2.6-17.2%), and median OS was 11.1 months (95% CI, 8.9-13.7) and 6.6 months (95% CI, 5.4-9.4), respectively. In the 1 L-mn subgroup, median OS measured from start of 1 L chemotherapy was 18.7 months (95% CI, 15.4-20.6). Across both subgroups, 20.7% had an infusion-related reaction of any grade. Other common treatment-related adverse events (TRAEs) of any grade included fatigue (10.0%) and nausea (6.7%). Treatment-related serious adverse events occurred in 4.0% of patients. Overall, 8.7% had a grade ≥3 TRAE, including 1 treatment-related death. CONCLUSION: Avelumab showed clinical activity and an acceptable safety profile in patients with GC/GEJC. TRIAL REGISTRATION: ClinicalTrials.gov NCT01772004 ; registered 21 January 2013. More... »

PAGES

30

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-019-0508-1

DOI

http://dx.doi.org/10.1186/s40425-019-0508-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111909070

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30717797


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, 03722, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "Hyun Cheol", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Sarah Cannon Research Institute/University College London, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arkenau", 
        "givenName": "Hendrik-Tobias", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jeeyun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, 03722, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rha", 
        "givenName": "Sun Young", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oh", 
        "givenName": "Do-Youn", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centrum Onkologii Instytut", 
          "id": "https://www.grid.ac/institutes/grid.418165.f", 
          "name": [
            "Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wyrwicz", 
        "givenName": "Lucjan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asan Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413967.e", 
          "name": [
            "Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kang", 
        "givenName": "Yoon-Koo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seoul National University Bundang Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412480.b", 
          "name": [
            "Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Keun-Wook", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sarah Cannon", 
          "id": "https://www.grid.ac/institutes/grid.419513.b", 
          "name": [
            "Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Infante", 
        "givenName": "Jeffrey R.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Inje University", 
          "id": "https://www.grid.ac/institutes/grid.411612.1", 
          "name": [
            "Inje University College of Medicine, Busan, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Sung Sook", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Icahn School of Medicine at Mount Sinai", 
          "id": "https://www.grid.ac/institutes/grid.59734.3c", 
          "name": [
            "Queens Cancer Center, Mt Sinai School of Medicine, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kemeny", 
        "givenName": "Margaret", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Charit\u00e9 Comprehensive Cancer Center, Charit\u00e9platz 1, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Keilholz", 
        "givenName": "Ulrich", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital Olomouc", 
          "id": "https://www.grid.ac/institutes/grid.412730.3", 
          "name": [
            "Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, Olomouc, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Melichar", 
        "givenName": "Bohuslav", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cedars-Sinai Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.50956.3f", 
          "name": [
            "Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mita", 
        "givenName": "Alain", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Freeman Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415050.5", 
          "name": [
            "Northern Centre for Cancer Care and Newcastle University, Freeman Hospital, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Plummer", 
        "givenName": "Ruth", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Bordeaux", 
          "id": "https://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "Medical Oncology, Bordeaux University Hospital, Bordeaux CEDEX, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Denis", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMD Serono (United States)", 
          "id": "https://www.grid.ac/institutes/grid.467308.e", 
          "name": [
            "EMD Serono, Inc, Billerica, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gelb", 
        "givenName": "Arnold B.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMD Serono (United States)", 
          "id": "https://www.grid.ac/institutes/grid.467308.e", 
          "name": [
            "EMD Serono, Inc, Billerica, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "Huiling", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMD Serono (United States)", 
          "id": "https://www.grid.ac/institutes/grid.467308.e", 
          "name": [
            "EMD Serono, Inc, Billerica, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hong", 
        "givenName": "Janet", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "EMD Serono, Inc, Billerica, USA", 
            "Present address: AstraZeneca Pharmaceuticals LP, Gaithersburg, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chand", 
        "givenName": "Vikram", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brown University", 
          "id": "https://www.grid.ac/institutes/grid.40263.33", 
          "name": [
            "Brown University, Providence, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Safran", 
        "givenName": "Howard", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.18632/oncotarget.8169", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003612958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70102-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003770145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-15-0059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014297921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.29864", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018926209"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.29210", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018963471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)00175-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020208654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.13922", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026248915"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30364-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027076842"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)62004-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029003642"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11523-016-0421-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037882822", 
          "https://doi.org/10.1007/s11523-016-0421-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.47.1102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041282863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.36.2236", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041387125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mjt.0000000000000156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052812271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mjt.0000000000000156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052812271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mjt.0000000000000156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052812271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-15-0176", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063282536"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30239-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30239-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30239-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30239-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30240-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.71.6795", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084512068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-17-0025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090389962"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-17-0025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090389962"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)31827-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092128619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx440.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092171961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-017-0300-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092818845", 
          "https://doi.org/10.1186/s40425-017-0300-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30900-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099606489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.77.6385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101034912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.31293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101165918"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2018.0013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101546919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2018.0013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101546919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2018.0013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101546919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)31257-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104380546"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41591-018-0101-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105584578", 
          "https://doi.org/10.1038/s41591-018-0101-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41591-018-0101-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105584578", 
          "https://doi.org/10.1038/s41591-018-0101-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105781814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdy264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105781814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.4014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106846447"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: We evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1\u2009L-mn) or second-line (2\u2009L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy.\nMETHODS: In a phase 1b expansion cohort, patients without (1\u2009L-mn) or with (2\u2009L) disease progression following first-line chemotherapy for advanced GC/GEJC received avelumab 10\u2009mg/kg intravenously every 2\u2009weeks. Endpoints included best overall response, progression-free survival (PFS), overall survival (OS), and safety.\nRESULTS: Overall, 150 patients were enrolled (1\u2009L-mn, n\u2009=\u200990; 2\u2009L, n\u2009=\u200960) and median follow-up in the 1\u2009L-mn and 2\u2009L subgroups was 36.0 and 33.7\u2009months, respectively. The confirmed objective response rate was 6.7% in both subgroups (95% CI, 2.5-13.9% and 1.8-16.2%, respectively), including complete responses in 2.2% of the 1\u2009L-mn subgroup (n\u2009=\u20092). In the 1\u2009L-mn and 2\u2009L subgroups, median duration of response was 21.4\u2009months (95% CI, 4.0-not estimable) and 3.5\u2009months (95% CI, 2.8-8.3) and disease control rates were 56.7 and 28.3%, respectively. Median PFS in the 1\u2009L-mn and 2\u2009L subgroups was 2.8\u2009months (95% CI, 2.3-4.1) and 1.4\u2009months (95% CI, 1.3-1.5), with 6-month PFS rates of 23.0% (95% CI, 14.7-32.4%) and 7.9% (95% CI, 2.6-17.2%), and median OS was 11.1\u2009months (95% CI, 8.9-13.7) and 6.6\u2009months (95% CI, 5.4-9.4), respectively. In the 1\u2009L-mn subgroup, median OS measured from start of 1\u2009L chemotherapy was 18.7\u2009months (95% CI, 15.4-20.6). Across both subgroups, 20.7% had an infusion-related reaction of any grade. Other common treatment-related adverse events (TRAEs) of any grade included fatigue (10.0%) and nausea (6.7%). Treatment-related serious adverse events occurred in 4.0% of patients. Overall, 8.7% had a grade\u2009\u22653 TRAE, including 1 treatment-related death.\nCONCLUSION: Avelumab showed clinical activity and an acceptable safety profile in patients with GC/GEJC.\nTRIAL REGISTRATION: ClinicalTrials.gov NCT01772004 ; registered 21 January 2013.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-019-0508-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Avelumab (anti\u2013PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial", 
    "pagination": "30", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "36e483c6363ed81498887613c901d013514d198621c887c436e72c782606c5d8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30717797"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-019-0508-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111909070"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-019-0508-1", 
      "https://app.dimensions.ai/details/publication/pub.1111909070"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000336_0000000336/records_94804_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-019-0508-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0508-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0508-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0508-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0508-1'


 

This table displays all metadata directly associated to this object as RDF triples.

326 TRIPLES      21 PREDICATES      58 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-019-0508-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N4114027b99df44d4b9d6d218897a96d5
4 schema:citation sg:pub.10.1007/s11523-016-0421-1
5 sg:pub.10.1038/s41591-018-0101-z
6 sg:pub.10.1186/s40425-017-0300-z
7 https://doi.org/10.1001/jamaoncol.2018.0013
8 https://doi.org/10.1002/cncr.29864
9 https://doi.org/10.1002/cncr.31293
10 https://doi.org/10.1002/ijc.29210
11 https://doi.org/10.1016/s0140-6736(14)62004-3
12 https://doi.org/10.1016/s0140-6736(17)31827-5
13 https://doi.org/10.1016/s0140-6736(18)31257-1
14 https://doi.org/10.1016/s1470-2045(13)70102-5
15 https://doi.org/10.1016/s1470-2045(16)00175-3
16 https://doi.org/10.1016/s1470-2045(16)30364-3
17 https://doi.org/10.1016/s1470-2045(17)30239-5
18 https://doi.org/10.1016/s1470-2045(17)30240-1
19 https://doi.org/10.1016/s1470-2045(17)30900-2
20 https://doi.org/10.1093/annonc/mdx440.020
21 https://doi.org/10.1093/annonc/mdy264
22 https://doi.org/10.1097/mjt.0000000000000156
23 https://doi.org/10.1158/1078-0432.ccr-17-0025
24 https://doi.org/10.1158/2326-6066.cir-15-0059
25 https://doi.org/10.1158/2326-6066.cir-15-0176
26 https://doi.org/10.1200/jco.2011.36.2236
27 https://doi.org/10.1200/jco.2012.47.1102
28 https://doi.org/10.1200/jco.2016.71.6795
29 https://doi.org/10.1200/jco.2017.35.15_suppl.4014
30 https://doi.org/10.1200/jco.2017.77.6385
31 https://doi.org/10.18632/oncotarget.13922
32 https://doi.org/10.18632/oncotarget.8169
33 schema:datePublished 2019-12
34 schema:datePublishedReg 2019-12-01
35 schema:description BACKGROUND: We evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy. METHODS: In a phase 1b expansion cohort, patients without (1 L-mn) or with (2 L) disease progression following first-line chemotherapy for advanced GC/GEJC received avelumab 10 mg/kg intravenously every 2 weeks. Endpoints included best overall response, progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Overall, 150 patients were enrolled (1 L-mn, n = 90; 2 L, n = 60) and median follow-up in the 1 L-mn and 2 L subgroups was 36.0 and 33.7 months, respectively. The confirmed objective response rate was 6.7% in both subgroups (95% CI, 2.5-13.9% and 1.8-16.2%, respectively), including complete responses in 2.2% of the 1 L-mn subgroup (n = 2). In the 1 L-mn and 2 L subgroups, median duration of response was 21.4 months (95% CI, 4.0-not estimable) and 3.5 months (95% CI, 2.8-8.3) and disease control rates were 56.7 and 28.3%, respectively. Median PFS in the 1 L-mn and 2 L subgroups was 2.8 months (95% CI, 2.3-4.1) and 1.4 months (95% CI, 1.3-1.5), with 6-month PFS rates of 23.0% (95% CI, 14.7-32.4%) and 7.9% (95% CI, 2.6-17.2%), and median OS was 11.1 months (95% CI, 8.9-13.7) and 6.6 months (95% CI, 5.4-9.4), respectively. In the 1 L-mn subgroup, median OS measured from start of 1 L chemotherapy was 18.7 months (95% CI, 15.4-20.6). Across both subgroups, 20.7% had an infusion-related reaction of any grade. Other common treatment-related adverse events (TRAEs) of any grade included fatigue (10.0%) and nausea (6.7%). Treatment-related serious adverse events occurred in 4.0% of patients. Overall, 8.7% had a grade ≥3 TRAE, including 1 treatment-related death. CONCLUSION: Avelumab showed clinical activity and an acceptable safety profile in patients with GC/GEJC. TRIAL REGISTRATION: ClinicalTrials.gov NCT01772004 ; registered 21 January 2013.
36 schema:genre research_article
37 schema:inLanguage en
38 schema:isAccessibleForFree true
39 schema:isPartOf N14ca9c5316344a04b0721f97e1d57b17
40 N94f008c561194c329418ad9adcc1d185
41 sg:journal.1049249
42 schema:name Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
43 schema:pagination 30
44 schema:productId N0ca41a996f9e48ea84201245ea8bf428
45 N9b558d9660184f8bbb6d11d78ab85968
46 Na280d78b4bc24a4c9d6b629364ae461a
47 Nbd700d264a964a808ed8e4312c67a834
48 Nec2945962a9948e9abe570addec8c857
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111909070
50 https://doi.org/10.1186/s40425-019-0508-1
51 schema:sdDatePublished 2019-04-11T09:05
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher Ndecd2211140e4409a132b6a958385351
54 schema:url https://link.springer.com/10.1186%2Fs40425-019-0508-1
55 sgo:license sg:explorer/license/
56 sgo:sdDataset articles
57 rdf:type schema:ScholarlyArticle
58 N02ce6b5e465a4b4f9b6739c456acfcc9 schema:name Sarah Cannon Research Institute/University College London, London, UK
59 rdf:type schema:Organization
60 N05af3d9c18444268b26c5abce471e7b8 schema:affiliation Nb421cb9a3f014d5e8bec9e566a9c7310
61 schema:familyName Rha
62 schema:givenName Sun Young
63 rdf:type schema:Person
64 N05b4b7e0138e4740a370e781f54355ac schema:affiliation https://www.grid.ac/institutes/grid.467308.e
65 schema:familyName Xiong
66 schema:givenName Huiling
67 rdf:type schema:Person
68 N0ca41a996f9e48ea84201245ea8bf428 schema:name dimensions_id
69 schema:value pub.1111909070
70 rdf:type schema:PropertyValue
71 N0e7f3edf75dc4d2cb6d2d8192dfa2a5b schema:affiliation https://www.grid.ac/institutes/grid.50956.3f
72 schema:familyName Mita
73 schema:givenName Alain
74 rdf:type schema:Person
75 N0f9d83bff2124a5e9d8e39551090e842 rdf:first N2a7cb5d41bab4f168ff9123f92c812fd
76 rdf:rest N51f5b2a27b564f52a48dec07791a07d4
77 N1072181420e64a209407bcc80222e6c4 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
78 schema:familyName Chand
79 schema:givenName Vikram
80 rdf:type schema:Person
81 N12fb54c753284e84a34a976f80fe536f schema:name Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, 03722, Seoul, South Korea
82 rdf:type schema:Organization
83 N14ca9c5316344a04b0721f97e1d57b17 schema:volumeNumber 7
84 rdf:type schema:PublicationVolume
85 N1758d7d5944c46dc804c50ad329d503e rdf:first N1072181420e64a209407bcc80222e6c4
86 rdf:rest N34145c31ea554c93b5f6800d87e7c2bb
87 N18af05518e744bce842e0c3728060b56 schema:affiliation https://www.grid.ac/institutes/grid.419513.b
88 schema:familyName Infante
89 schema:givenName Jeffrey R.
90 rdf:type schema:Person
91 N1cebdade42f541c7bb21a40f8a20cca0 rdf:first Nc0f6d72081244a2da8910052d9519293
92 rdf:rest N847000bbacc243e78ef2a069ddb9c3aa
93 N20d4cea32c2b4b32aee765ab3e061d39 schema:affiliation N12fb54c753284e84a34a976f80fe536f
94 schema:familyName Chung
95 schema:givenName Hyun Cheol
96 rdf:type schema:Person
97 N232ea672d1f540b29ad8ea920fe102d0 rdf:first N8a0815b770fa4a719eef5219694d2308
98 rdf:rest Na71dd34f61974f45805d84d8077b824a
99 N255c3b1a9bc845c79d9fd837fb18117c rdf:first N18af05518e744bce842e0c3728060b56
100 rdf:rest Ne96650194e024d44afe1fdf9b39790d3
101 N26c2c1d12a4d44f9af88113cc1832daf schema:affiliation https://www.grid.ac/institutes/grid.467308.e
102 schema:familyName Hong
103 schema:givenName Janet
104 rdf:type schema:Person
105 N288ede3b9a8d4842bdb404fac41670b1 schema:affiliation https://www.grid.ac/institutes/grid.59734.3c
106 schema:familyName Kemeny
107 schema:givenName Margaret
108 rdf:type schema:Person
109 N2a7cb5d41bab4f168ff9123f92c812fd schema:affiliation N5908b1246de64623a1cae61d8f68c381
110 schema:familyName Oh
111 schema:givenName Do-Youn
112 rdf:type schema:Person
113 N34145c31ea554c93b5f6800d87e7c2bb rdf:first N5521fb87757c41d5bfc984f25c4c443c
114 rdf:rest rdf:nil
115 N3de42dbe392747d592726c06a17451a7 rdf:first N05b4b7e0138e4740a370e781f54355ac
116 rdf:rest Nfe0be4e0422149d595b4efe836754f54
117 N4114027b99df44d4b9d6d218897a96d5 rdf:first N20d4cea32c2b4b32aee765ab3e061d39
118 rdf:rest N66536812cb914fd08ef65a57a34ce76c
119 N41a7a53088a440b5930c186a0478155e schema:name Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
120 rdf:type schema:Organization
121 N509fadc07dc1437f94991190cf8e4762 schema:name Charité Comprehensive Cancer Center, Charitéplatz 1, Berlin, Germany
122 rdf:type schema:Organization
123 N51f5b2a27b564f52a48dec07791a07d4 rdf:first N87c8f6f8dab244439b0a8da85f85b337
124 rdf:rest N9b40da11d8cb4e83bf4b144e45f92f09
125 N529fe890c1be4a4a9a977c0da934cab2 schema:affiliation N02ce6b5e465a4b4f9b6739c456acfcc9
126 schema:familyName Arkenau
127 schema:givenName Hendrik-Tobias
128 rdf:type schema:Person
129 N5521fb87757c41d5bfc984f25c4c443c schema:affiliation https://www.grid.ac/institutes/grid.40263.33
130 schema:familyName Safran
131 schema:givenName Howard
132 rdf:type schema:Person
133 N5908b1246de64623a1cae61d8f68c381 schema:name Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
134 rdf:type schema:Organization
135 N66536812cb914fd08ef65a57a34ce76c rdf:first N529fe890c1be4a4a9a977c0da934cab2
136 rdf:rest N1cebdade42f541c7bb21a40f8a20cca0
137 N69c581c064034465b0180cb70aa80bdb rdf:first N7085f198133047e19d2662ddb447b0ef
138 rdf:rest N255c3b1a9bc845c79d9fd837fb18117c
139 N7085f198133047e19d2662ddb447b0ef schema:affiliation https://www.grid.ac/institutes/grid.412480.b
140 schema:familyName Lee
141 schema:givenName Keun-Wook
142 rdf:type schema:Person
143 N847000bbacc243e78ef2a069ddb9c3aa rdf:first N05af3d9c18444268b26c5abce471e7b8
144 rdf:rest N0f9d83bff2124a5e9d8e39551090e842
145 N87c8f6f8dab244439b0a8da85f85b337 schema:affiliation https://www.grid.ac/institutes/grid.418165.f
146 schema:familyName Wyrwicz
147 schema:givenName Lucjan
148 rdf:type schema:Person
149 N8a0815b770fa4a719eef5219694d2308 schema:affiliation https://www.grid.ac/institutes/grid.42399.35
150 schema:familyName Smith
151 schema:givenName Denis
152 rdf:type schema:Person
153 N94f008c561194c329418ad9adcc1d185 schema:issueNumber 1
154 rdf:type schema:PublicationIssue
155 N9b40da11d8cb4e83bf4b144e45f92f09 rdf:first Nb1e75f34da784b91a9b00c231330a72f
156 rdf:rest N69c581c064034465b0180cb70aa80bdb
157 N9b558d9660184f8bbb6d11d78ab85968 schema:name readcube_id
158 schema:value 36e483c6363ed81498887613c901d013514d198621c887c436e72c782606c5d8
159 rdf:type schema:PropertyValue
160 N9e0576d8e2bd4b1483957ddb54a8fd8a rdf:first Nd80a7729ac734b1cb616aeec6311b184
161 rdf:rest N232ea672d1f540b29ad8ea920fe102d0
162 Na280d78b4bc24a4c9d6b629364ae461a schema:name nlm_unique_id
163 schema:value 101620585
164 rdf:type schema:PropertyValue
165 Na71dd34f61974f45805d84d8077b824a rdf:first Nd8065b8c32034955882cfa146cc5d719
166 rdf:rest N3de42dbe392747d592726c06a17451a7
167 Nb1e75f34da784b91a9b00c231330a72f schema:affiliation https://www.grid.ac/institutes/grid.413967.e
168 schema:familyName Kang
169 schema:givenName Yoon-Koo
170 rdf:type schema:Person
171 Nb421cb9a3f014d5e8bec9e566a9c7310 schema:name Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, 03722, Seoul, South Korea
172 rdf:type schema:Organization
173 Nbd700d264a964a808ed8e4312c67a834 schema:name doi
174 schema:value 10.1186/s40425-019-0508-1
175 rdf:type schema:PropertyValue
176 Nc0f6d72081244a2da8910052d9519293 schema:affiliation N41a7a53088a440b5930c186a0478155e
177 schema:familyName Lee
178 schema:givenName Jeeyun
179 rdf:type schema:Person
180 Nc3585d620f7c48d685f5e7dc44aeec58 rdf:first N0e7f3edf75dc4d2cb6d2d8192dfa2a5b
181 rdf:rest N9e0576d8e2bd4b1483957ddb54a8fd8a
182 Ncc042192d28a409aa9d5d9787b1fee66 rdf:first Nff50f951890a4861aa84ad3089388024
183 rdf:rest Nc3585d620f7c48d685f5e7dc44aeec58
184 Nd8065b8c32034955882cfa146cc5d719 schema:affiliation https://www.grid.ac/institutes/grid.467308.e
185 schema:familyName Gelb
186 schema:givenName Arnold B.
187 rdf:type schema:Person
188 Nd80a7729ac734b1cb616aeec6311b184 schema:affiliation https://www.grid.ac/institutes/grid.415050.5
189 schema:familyName Plummer
190 schema:givenName Ruth
191 rdf:type schema:Person
192 Nd9ef0847c4114a9baafd33f05e0ed374 rdf:first N288ede3b9a8d4842bdb404fac41670b1
193 rdf:rest Nee0205049557443f89f1b3d11b2168ae
194 Ndecd2211140e4409a132b6a958385351 schema:name Springer Nature - SN SciGraph project
195 rdf:type schema:Organization
196 Ne64af5b4a76b45a4a2253507ba337058 schema:affiliation https://www.grid.ac/institutes/grid.411612.1
197 schema:familyName Lee
198 schema:givenName Sung Sook
199 rdf:type schema:Person
200 Ne96650194e024d44afe1fdf9b39790d3 rdf:first Ne64af5b4a76b45a4a2253507ba337058
201 rdf:rest Nd9ef0847c4114a9baafd33f05e0ed374
202 Nec2945962a9948e9abe570addec8c857 schema:name pubmed_id
203 schema:value 30717797
204 rdf:type schema:PropertyValue
205 Nee0205049557443f89f1b3d11b2168ae rdf:first Nf2654136b43e49379355854126f00e0f
206 rdf:rest Ncc042192d28a409aa9d5d9787b1fee66
207 Nf2654136b43e49379355854126f00e0f schema:affiliation N509fadc07dc1437f94991190cf8e4762
208 schema:familyName Keilholz
209 schema:givenName Ulrich
210 rdf:type schema:Person
211 Nfe0be4e0422149d595b4efe836754f54 rdf:first N26c2c1d12a4d44f9af88113cc1832daf
212 rdf:rest N1758d7d5944c46dc804c50ad329d503e
213 Nff50f951890a4861aa84ad3089388024 schema:affiliation https://www.grid.ac/institutes/grid.412730.3
214 schema:familyName Melichar
215 schema:givenName Bohuslav
216 rdf:type schema:Person
217 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
218 schema:name Medical and Health Sciences
219 rdf:type schema:DefinedTerm
220 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
221 schema:name Oncology and Carcinogenesis
222 rdf:type schema:DefinedTerm
223 sg:journal.1049249 schema:issn 2051-1426
224 schema:name Journal for ImmunoTherapy of Cancer
225 rdf:type schema:Periodical
226 sg:pub.10.1007/s11523-016-0421-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037882822
227 https://doi.org/10.1007/s11523-016-0421-1
228 rdf:type schema:CreativeWork
229 sg:pub.10.1038/s41591-018-0101-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1105584578
230 https://doi.org/10.1038/s41591-018-0101-z
231 rdf:type schema:CreativeWork
232 sg:pub.10.1186/s40425-017-0300-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1092818845
233 https://doi.org/10.1186/s40425-017-0300-z
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1001/jamaoncol.2018.0013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101546919
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1002/cncr.29864 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018926209
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1002/cncr.31293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101165918
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1002/ijc.29210 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018963471
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1016/s0140-6736(14)62004-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029003642
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1016/s0140-6736(17)31827-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092128619
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/s0140-6736(18)31257-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104380546
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1016/s1470-2045(13)70102-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003770145
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/s1470-2045(16)00175-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020208654
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/s1470-2045(16)30364-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027076842
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/s1470-2045(17)30239-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084052547
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/s1470-2045(17)30240-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084052548
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/s1470-2045(17)30900-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099606489
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1093/annonc/mdx440.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092171961
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1093/annonc/mdy264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105781814
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1097/mjt.0000000000000156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052812271
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1158/1078-0432.ccr-17-0025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090389962
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1158/2326-6066.cir-15-0059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014297921
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1158/2326-6066.cir-15-0176 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063282536
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.2011.36.2236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041387125
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.2012.47.1102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041282863
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.2016.71.6795 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084512068
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2017.35.15_suppl.4014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106846447
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1200/jco.2017.77.6385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101034912
282 rdf:type schema:CreativeWork
283 https://doi.org/10.18632/oncotarget.13922 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026248915
284 rdf:type schema:CreativeWork
285 https://doi.org/10.18632/oncotarget.8169 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003612958
286 rdf:type schema:CreativeWork
287 https://www.grid.ac/institutes/grid.40263.33 schema:alternateName Brown University
288 schema:name Brown University, Providence, USA
289 rdf:type schema:Organization
290 https://www.grid.ac/institutes/grid.411612.1 schema:alternateName Inje University
291 schema:name Inje University College of Medicine, Busan, South Korea
292 rdf:type schema:Organization
293 https://www.grid.ac/institutes/grid.412480.b schema:alternateName Seoul National University Bundang Hospital
294 schema:name Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.412730.3 schema:alternateName University Hospital Olomouc
297 schema:name Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, Olomouc, Czech Republic
298 rdf:type schema:Organization
299 https://www.grid.ac/institutes/grid.413967.e schema:alternateName Asan Medical Center
300 schema:name Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.415050.5 schema:alternateName Freeman Hospital
303 schema:name Northern Centre for Cancer Care and Newcastle University, Freeman Hospital, Newcastle upon Tyne, UK
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
306 schema:name EMD Serono, Inc, Billerica, USA
307 Present address: AstraZeneca Pharmaceuticals LP, Gaithersburg, USA
308 rdf:type schema:Organization
309 https://www.grid.ac/institutes/grid.418165.f schema:alternateName Centrum Onkologii Instytut
310 schema:name Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland
311 rdf:type schema:Organization
312 https://www.grid.ac/institutes/grid.419513.b schema:alternateName Sarah Cannon
313 schema:name Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA
314 rdf:type schema:Organization
315 https://www.grid.ac/institutes/grid.42399.35 schema:alternateName Centre Hospitalier Universitaire de Bordeaux
316 schema:name Medical Oncology, Bordeaux University Hospital, Bordeaux CEDEX, France
317 rdf:type schema:Organization
318 https://www.grid.ac/institutes/grid.467308.e schema:alternateName EMD Serono (United States)
319 schema:name EMD Serono, Inc, Billerica, USA
320 rdf:type schema:Organization
321 https://www.grid.ac/institutes/grid.50956.3f schema:alternateName Cedars-Sinai Medical Center
322 schema:name Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
323 rdf:type schema:Organization
324 https://www.grid.ac/institutes/grid.59734.3c schema:alternateName Icahn School of Medicine at Mount Sinai
325 schema:name Queens Cancer Center, Mt Sinai School of Medicine, New York, USA
326 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...